US · Healthcare · Biotechnology
EPS came in at -0.74 against a street estimate of -0.78 — a beat of 5.1%.
Analysts rate Crescent Biopharma, Inc. a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $31.50.
| Fund | Stake |
|---|---|
| FMR Inc | 11.13% |
| Bvf Inc | 7.40% |
| Fairmount Funds Management LLC | 7.40% |
| VR Adviser, LLC | 5.74% |
| Logos Global Management LP | 5.11% |
| FCPM III SERVICES BV | 4.52% |
| Balyasny Asset Management LLC | 4.48% |
| Vestal Point Capital LP | 4.39% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 CRESCENT BIOPHARMA, INC. - Q2 2026 SUMMARY HEADLINE NUMBERS • Cash position: $171,593,000 as of June 30, 2026 (down from $213,192,000 at December 31 | 2026-07-30 |
| Results announced · Q3 2026 CRESCENT BIOPHARMA Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $171.6 million as of June 30, 2026 • Pro forma ca | 2026-07-30 |
| Company announcement · Q3 2026 CRESCENT BIOPHARMA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Offering Size: 8,094,793 ordinary shares at $14.50 per share, plus 525,897 pre-funded | 2026-07-15 |
| Results announced · Q3 2026 CRESCENT BIOPHARMA, INC. (CBIO) - 8-K SUMMARY HEADLINE NUMBERS • Cash and cash equivalents as of June 30, 2026: approximately $171.6 million • Stock | 2026-07-14 |
| Shareholder vote results · Q2 2026 CRESCENT BIOPHARMA, INC. (CBIO) - FORM 8-K SUMMARY HEADLINE NUMBERS • As of April 7, 2026 (record date): 27,571,935 ordinary shares outstanding • As | 2026-06-03 |
| Quarterly report · Q1 2026 CRESCENT BIOPHARMA, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $189.2 million as of March 31, 2026 (down from $213.2 million at D | 2026-04-29 |
| Proxy statement · Q2 2026 CRESCENT BIOPHARMA, INC. — PROXY SUMMARY FOR SHAREHOLDERS --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1A: Elect Jonathan Violin, Ph.D., as Class | 2026-04-21 |
| Annual report FY2025 CRESCENT BIOPHARMA, INC. — SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market Capitalization (as of June 30, 2025): approximately $177.2 million | 2026-02-26 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Crescent Biopharma, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.